StarD13 is a tumor suppressor in breast cancer that regulates cell motility and invasion

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1499-1511

  Hanna, Samer ^a   Khalil, Bassem ^a   Nasrallah, Anita ^a   Saykali, Bechara A ^a   Sobh, Rania ^a   Nasser, Selim ^a   El Sibai, Mirvat ^a  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

Breast cancer; Cell motility; Rac; RhoA; StarD13

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PROTEIN CDC42; PROTEIN STARD13; RAC PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER TISSUE; CELL INVASION; CELL MOTILITY; CELL MOTION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; NEOPLASM INVASIVENESS; RAC GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; TUMOR SUPPRESSOR PROTEINS;

EID: 84899076827     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2330     Document Type: Article

References (40)

1. Jiang P, Enomoto A and Takahashi M: Cell biology of the movement of breast cancer cells: intracellular signalling and the actin cytoskeleton. Cancer Lett 284: 122-130, 2009.
2. Claus EB, Stowe M and Carter D: Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93: 1811-1817, 2001. (Pubitemid 33150454)
3. Bombonati A and Sgroi DC: The molecular pathology of breast cancer progression. J Pathol 223: 307-317, 2011.
4. van Golen KL: Inflammatory breast cancer: relationship between growth factor signaling and motility in aggressive cancers. Breast Cancer Res 5: 174-179, 2003.
5. Sahai E and Marshall CJ: RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142, 2002.
6. Tang Y, Olufemi L, Wang MT and Nie D: Role of Rho GTPases in breast cancer. Front Biosci 13: 759-776, 2008. (Pubitemid 351599780)
7. Etienne-Manneville S and Hall A: Rho GTPases in cell biology. Nature 420: 629-635, 2002. (Pubitemid 36764489)
8. Vega FM and Ridley AJ: Rho GTPases in cancer cell biology. FEBS Lett 582: 2093-2101, 2008.
9. Takai Y, Sasaki T and Matozaki T: Small GTP-binding proteins. Physiol Rev 81: 153-208, 2001. (Pubitemid 32098004)
10. Moon SY and Zheng Y: Rho GTPase-activating proteins in cell regulation. Trends Cell Biol 13: 13-22, 2003. (Pubitemid 35453891)
11. Grise F, Bidaud A and Moreau V: Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta 1795: 137-151, 2009.
12. Ching YP, Wong CM, Chan SF, et al: Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 278: 10824-10830, 2003.
13. Ullmannova V and Popescu NC: Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol 29: 1127-1132, 2006.
14. Thorsell AG, Lee WH, Persson C, et al: Comparative structural analysis of lipid binding START domains. PLoS One 6: e19521, 2011.
15. Liao YC and Lo SH: Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol 40: 843-847, 2008.
16. El-Sitt S, Khalil BD, Hanna S, El-Sabban M, Fakhreddine N and El-Sibai M: DLC2/StarD13 plays a role of a tumor suppressor in astrocytoma. Oncol Rep 28: 511-518, 2012.
17. Nobes CD and Hall A: Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 144: 1235-1244, 1999. (Pubitemid 29157301)
18. Wolfenson H, Henis YI, Geiger B and Bershadsky AD: The heel and toe of the cell's foot: a multifaceted approach for understanding the structure and dynamics of focal adhesions. Cell Motil Cytoskeleton 66: 1017-1029, 2009.
19. Arjonen A, Kaukonen R and Ivaska J: Filopodia and adhesion in cancer cell motility. Cell Adh Migr 5: 421-430, 2011.
20. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA and Collard JG: Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol 147: 1009-1022, 1999.
21. Cox EA, Sastry SK and Huttenlocher A: Integrin-mediated adhesion regulates cell polarity and membrane protrusion through the Rho family of GTPases. Mol Biol Cell 12: 265-277, 2001. (Pubitemid 33051574)
22. Kaverina I, Krylyshkina O and Small JV: Regulation of substrate adhesion dynamics during cell motility. Int J Biochem Cell Biol 34: 746-761, 2002. (Pubitemid 34304165)
23. El-Sibai M, Pertz O, Pang H, et al: RhoA/ROCK-mediated switching between Cdc42- and Rac1-dependent protrusion in MTLn3 carcinoma cells. Exp Cell Res 314: 1540-1552, 2008.
24. Banyard J, Anand-Apte B, Symons M and Zetter BR: Motility and invasion are differentially modulated by Rho family GTPases. Oncogene 19: 580-591, 2000. (Pubitemid 30099372)
25. Vial E, Sahai E and Marshall CJ: ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4: 67-79, 2003. (Pubitemid 36904162)
26. Tkach V, Bock E and Berezin V: The role of RhoA in the regulation of cell morphology and motility. Cell Motil Cytoskeleton 61: 21-33, 2005. (Pubitemid 40604948)
27. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS and Popescu NC: Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 58: 2196-2199, 1998. (Pubitemid 28232908)
28. Yuan BZ, Durkin ME and Popescu NC: Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet 140: 113-117, 2003. (Pubitemid 36349010)
29. Durkin ME, Yuan BZ, Zhou X, et al: DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 11: 1185-1207, 2007. (Pubitemid 350037059)
30. Yuan BZ, Zhou X, Durkin ME, et al: DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene 22: 445-450, 2003. (Pubitemid 36194340)
31. Ng IO, Liang ZD, Cao L and Lee TK: DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res 60: 6581-6584, 2000.
32. Kim TY, Vigil D, Der CJ and Juliano RL: Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev 28: 77-83, 2009.
33. Zhong D, Zhang J, Yang S, et al: The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J Cell Sci 122: 414-424, 2009.
34. Shih YP, Takada Y and Lo SH: Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells. Mol Cancer Res 10: 34-39, 2012.
35. Cao X, Voss C, Zhao B, Kaneko T and Li SS: Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation. Proc Natl Acad Sci USA 109: 1455-1460, 2012.
36. Massague J: TGFbeta in Cancer. Cell 134: 215-230, 2008.
37. Wang Y and McNiven MA: Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol 196: 375-385, 2012.
38. Pille JY, Denoyelle C, Varet J, et al: Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 11: 267-274, 2005.
39. Wu M, Wu ZF, Rosenthal DT, Rhee EM and Merajver SD: Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. Cancer 116: 2768-2782, 2010.
40. Sahai E and Marshall CJ: Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 5: 711-719, 2003. (Pubitemid 36986778)